抗RNPC-3抗体与系统性硬化症中重度胃肠动力障碍相关
该研究在约翰霍普金斯和匹兹堡SSc队列中分析抗RNPC-3抗体与胃肠道并发症的关联。发现抗RNPC-3阳性患者中重度GI功能障碍比例更高(36% vs 15%,P≤0.01),且更常见男性、非裔美国人、食管动力障碍和ILD。校正混杂后,中重度GI疾病与抗RNPC-3抗体相关(OR 3.8,95%CI 1.0-14.3)。
要点
- 抗RNPC-3阳性SSc患者中重度GI功能障碍比例显著高于阴性患者(36% vs 15%)。
- 抗RNPC-3阳性患者更常见男性、非裔美国人、食管动力障碍和ILD。
- 校正混杂后,中重度GI疾病与抗RNPC-3抗体相关(OR 3.8,95%CI 1.0-14.3)。
核心结论
- SSc患者中抗RNPC-3抗体与中重度胃肠道疾病和ILD相关,阳性者更可能为男性和非裔美国人。
研究设计与样本
- 研究纳入约翰霍普金斯SSc队列中有或无严重GI功能障碍(依赖全肠外营养)的患者血清进行抗RNPC-3抗体筛查,并在匹兹堡大学/UPMCSSc队列中验证。
主要发现
- 发现队列中,严重GI功能障碍患者(n=37)抗RNPC-3阳性率14%,无GI功能障碍者(n=38)为3%(P=0.11)。
- 匹兹堡队列中,抗RNPC-3阳性患者中重度GI功能障碍(Medsger GI评分≥2)占36%,阴性患者占15%(P≤0.01)。
- 抗RNPC-3阳性患者更常见男性(31% vs 15%,P=0.04)、非裔美国人(18% vs 6%,P=0.02)、食管动力障碍(93% vs 62%,P<0.01)和ILD(77% vs 35%,P<0.01)。
- 校正相关协变量和混杂因素后,中重度GI疾病与抗RNPC-3抗体相关(OR 3.8,95%CI 1.0-14.3),ILD呈边缘显著(OR 2.8,95%CI 1.0-8.2)。
关键数值与推荐
- 中重度GI功能障碍定义为Medsger GI评分≥2。
- 严重GI功能障碍定义为依赖全肠外营养。
临床怎么用
- 对SSc患者检测抗RNPC-3抗体可能有助于识别中重度GI疾病和ILD高风险亚组。
局限性
- 发现队列样本量小,抗RNPC-3阳性率差异未达统计学显著性(P=0.11)。
- 结论需在更大队列中进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the association of anti-RNPC-3 antibodies in patients with systemic sclerosis (scleroderma or SSc) with selected gastrointestinal (GI) tract complications. METHODS: Sera from patients with SSc with or without severe GI dysfunction (total parenteral nutrition dependence) from the Johns Hopkins Scleroderma Center were screened for anti-RNPC-3 antibodies. We then examined anti-RNPC-3-positive cases and negative SSc controls from the University of Pittsburgh and the University of Pittsburgh Medical Center (UPMC) scleroderma cohort to confirm our findings and to examine whether specific GI features were associated with anti-RNPC-3 antibodies. RESULTS: In the discovery cohort, patients with SSc with severe GI dysfunction (n = 37) and without GI dysfunction (n = 38) were screened for anti-RNPC-3 antibodies. The former were more likely to have anti-RNPC-3 antibodies (14% versus 3%; P = 0.11). In the Pittsburgh cohort, moderate-to-severe GI dysfunction (Medsger GI score ≥2) was present in 36% of anti-RNPC-3-positive patients versus 15% of anti-RNPC-3-negative patients (P ≤ 0.01). Anti-RNPC-3-positive patients were more likely to be male (31% versus 15%; P = 0.04), African American (18% versus 6%; P = 0.02), have esophageal dysmotility (93% versus 62%; P < 0.01), and interstitial lung disease (ILD) (77% versus 35%; P < 0.01). After adjusting for relevant covariates and potential confounders, moderate-to-severe GI disease was associated with anti-RNPC-3 antibodies (odds ratio [OR] 3.8 [95% confidence interval (95% CI) 1.0-14.3]), and ILD trended toward significance (OR 2.8 [95% CI 1.0-8.2]). CONCLUSION: Patients with SSc and anti-RNPC-3 antibodies are more likely to be male and African American and to have moderate-to-severe GI disease and ILD. Further studies on larger patient cohorts may be helpful in further defining subsets of patients with SSc at risk for severe GI involvement.
引用
- McMahan ZH, Domsic RT, Zhu L, et al. Anti-RNPC-3 (U11/U12) Antibodies in Systemic Sclerosis in Patients With Moderate-to-Severe Gastrointestinal Dysmotility. Arthritis Care Res (Hoboken). 2019. PMID: 30242973. doi:10.1002/acr.23763
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。